New Therapeutic Antibody Discovery Collaboration New Therapeutic Antibody Discovery Collaboration Proprietary antibody libraries to help discover therapeutic antibodies against multiple targets
Partnership with IBM to accelerate new antibody therapies Partnership with IBM to accelerate new antibody therapies Boehringer Ingelheim collaborates with IBM to advance generative AI and foundation models for therapeutic antibody development
PRRS vaccine discovery for swine PRRS vaccine discovery for swine PRRS vaccine, an unexpected scientific discovery. Our team developed the first vaccine against Porcine Reproductive and Respiratory Syndrome in pigs.
Trailr2-cdh17-antibody-phase1-trial Trailr2-cdh17-antibody-phase1-trial Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
Monoclonal Antibody Production | Bioxcellence | Boehringer Ingelheim Monoclonal Antibody Production | Bioxcellence | Boehringer Ingelheim Explore our advanced capabilities in antibody production, and learn about the unique features of monoclonal & polyclonal antibodies.
Agreement-to-acquire-NBE-Therapeutics Agreement-to-acquire-NBE-Therapeutics Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.
Collaboration-with-OxfordBioTherapeutics Collaboration-with-OxfordBioTherapeutics Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
Biotherapeutics Discovery Biotherapeutics Discovery We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.
IL-11 inhibitor antibody clinical development launched IL-11 inhibitor antibody clinical development launched Boehringer Ingelheim has launched clinical development of its first-in-class IL-11 inhibitor antibody as a fibrotic disease treatment
Drug Discovery at Boehringer Ingelheim Drug Discovery at Boehringer Ingelheim Find out more about the drug discovery process at Boehringer Ingelheim
Protein Degraders in Cancer Protein Degraders in Cancer Boehringer Ingelheim scientists and their partners are exploring how protein degraders could bring so-called undruggable cancer targets within reach
License deal with A*STAR to develop cancer antibodies License deal with A*STAR to develop cancer antibodies License deal with A*STAR to develop cancer antibodies
Monoclonal antibodies Boehringer Ingelheim and Invetx Monoclonal antibodies Boehringer Ingelheim and Invetx Boehringer Ingelheim and Invetx announce collaboration to discover, develop and commercialize novel veterinary monoclonal antibody biotherapeutics
Pulmonary Fibrosis: Early discovery makes all the difference Pulmonary Fibrosis: Early discovery makes all the difference Video taking a deep dive into pulmonary fibrosis. Visit an underwater world that brings to life the physical change PF has on the lungs.
Boehringer Ingelheim announces collaboration with MabGenesis Boehringer Ingelheim announces collaboration with MabGenesis Boehringer Ingelheim announces collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine
Spesolimab (BI 655130) Spesolimab (BI 655130) Spesolimab (BI 655130): IL36R antibody Netherton Syndrome
Acquisition expands research in cancer immunology Acquisition expands research in cancer immunology Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.